
NASDAQHealthcareMedical - Devices
Latest quote
$2.61
−$0.21 · -7.45%
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Previous close
$2.61
−$0.21 · -7.45%
Regular session · ET · Market data may be delayed.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Day range
Current $2.61
52-week range
Current $2.61
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
48
Mixed
Risk
33
Moderate Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Day range
Current $2.61
52-week range
Current $2.61
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70.75M USD | 69.35M USD | 65.32M USD | 57.92M USD | 52.08M USD |
| Cost of goods sold | 40.65M USD | 40.63M USD | 38.93M USD | 32.49M USD | 30.31M USD |
| Gross profit | 30.09M USD | 28.73M USD | 26.39M USD | 25.43M USD | 21.77M USD |
| Research and development | 10.13M USD | 9.1M USD | 8.21M USD | 6.04M USD | 5.62M USD |
| Selling, general, and administrative | 45.17M USD | 42.58M USD | 40.28M USD | 24.73M USD | 19.66M USD |
| Operating expenses | 55.3M USD | 51.68M USD | 48.49M USD | 30.77M USD | 25.28M USD |
| Interest income | 252.78K USD | 861.03K USD | 1.42M USD | 424.59K USD | 11.82K USD |
| Interest expense | 791.44K USD | 255.28K USD | 250.82K USD | 176.56K USD | 61.46K USD |
| Depreciation and amortization | 3.43M USD | 2.8M USD | 2.08M USD | 1.72M USD | 2.27M USD |
| Operating income | −25.21M USD | −22.95M USD | −22.1M USD | −5.35M USD | −3.51M USD |
| Net income | −29.34M USD | −20.57M USD | −22.9M USD | −3.08M USD | 827.39K USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.67
270.50% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.